Benefits
Urinary Calcium Modulation
In the single placebo-controlled trial cited here (69 calcium-stone-forming patients, 3 months), urinary calcium fell only in the subset who started with hypercalciuria. Overall urinary parameters did not differ significantly between groups, and the trial's stone passage and pain relief endpoints showed no difference. A lower urinary calcium in that subgroup is a laboratory measurement, not a demonstrated reduction in stones.
Kidney Stone Support Tradition
Used for centuries in South American traditional medicine for 'stone breaking,' Phyllanthus niruri remains a widely recommended botanical for urolithiasis support. Modern data amount to one placebo-controlled trial, which found lower urinary calcium in the hypercalciuric subset but no difference in stone passage or pain relief. It does not directly dissolve existing stones.
Liver Activity in Laboratory and Animal Models
The liver work cited here is preclinical: cell and animal models, summarized in two narrative reviews. No study cited on this page measured any liver outcome in a person, and systematic reviews of Phyllanthus for chronic hepatitis B have judged that evidence weak, citing low trial quality and variation in the herb itself. Treat this as laboratory background, not a reason to expect a liver benefit, and not a treatment for any liver condition.
Antioxidant Support
The polyphenol and ellagitannin fraction of Phyllanthus niruri shows free-radical scavenging activity in vitro. Scavenging in a test tube is not an antioxidant effect in a person. No study cited here measured any antioxidant, oxidative stress, or detoxification marker in humans.
Mechanism of action
Crystallization Inhibition
Aqueous extracts of Phyllanthus niruri interfere with calcium oxalate crystal nucleation and aggregation in laboratory models. Whether this translates into fewer stones in people is not established. The one human trial cited here measured stone passage and found no difference against placebo.
Urinary Calcium Normalization
One placebo-controlled trial found lower urinary calcium in its hypercalciuric subset only, with no significant difference in overall urinary parameters between groups. The mechanism is not defined and may involve renal calcium handling or intestinal absorption.
Antioxidant and Anti-Inflammatory Activity
Phyllanthin, hypophyllanthin, and ellagitannins scavenge reactive oxygen species and suppress inflammatory cytokine production in cell models. These are cell-model observations. Nothing cited here measured an antioxidant or liver effect in a person.
Hepatic Enzyme Modulation
Animal studies report lower liver enzymes (ALT, AST) in chemically induced liver injury models. This is animal work. No cited study measured a liver enzyme or any other liver outcome in a person, and an effect in a chemically injured animal liver does not predict a benefit in a healthy one.
Clinical trials
Randomized, placebo-controlled trial of Phyllanthus niruri (450 mg three times daily) for 3 months in 69 calcium-stone-forming patients randomized to Phyllanthus (33) or placebo (36), including patients with hypercalciuria. Urinary biochemistry, stone passage and pain relief were all assessed. (Nishiura et al, Urol Res)
69 calcium-stone-forming patients randomized, 33 to Phyllanthus and 36 to placebo, including a hypercalciuric subgroup.
Urinary calcium fell in the hypercalciuric subset only (4.8±1.0 to 3.4±1.1 mg/kg/24 h, p<0.05), with no significant adverse effects. The clinical endpoints were measured and were null: there were no significant differences in overall urinary parameters between groups, and stone passage and pain relief showed no difference between Phyllanthus and placebo. For a herb whose folk name means stone breaker, the absence of any effect on stone passage is the central result of this trial.
Comprehensive review of Phyllanthus niruri phytochemistry and pharmacology, including hepatoprotective, antiviral, antioxidant, and antilithic activity from preclinical and clinical studies. (Kaur et al, Phytother Res)
Narrative review of preclinical and human literature.
The review synthesizes evidence for hepatoprotective and antilithic activity, with stronger support for the urolithiasis indication than for antiviral hepatitis claims. Authors note Cochrane analyses of hepatitis B trials have been equivocal, supporting cautious framing of liver-disease claims while affirming the herb's traditional and pharmacologic profile.